Up­dat­ed: Flag­ship merges its trou­bled cir­cu­lar RNA com­pa­ny Laronde with nanopar­ti­cle start­up Sen­da

Laronde and Sen­da Bio­sciences, two biotech star­tups found­ed by Flag­ship Pi­o­neer­ing that col­lec­tive­ly raised more than $750 mil­lion, are merg­ing to form a new com­pa­ny called Sail Bio­med­i­cines, the life sci­ence in­vest­ment group an­nounced Thurs­day morn­ing.

Sail will com­bine Laronde’s cir­cu­lar RNA tech­nol­o­gy with Sen­da’s na­ture-de­rived nanopar­ti­cle plat­form. It’s a nat­ur­al pair­ing, since one of the biggest chal­lenges fac­ing ge­net­ic med­i­cines is find­ing new ways to de­liv­er them to the right cells in the body.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER